How much does tepotinib cost? Will it be included in medical insurance in 2024?

Tepotinib (Tepotinib) is a targeted therapy for non-small cell lung cancer (NSCLC), especially for cases carrying MET exon 14 skipping mutations. It effectively blocks the growth and spread of tumor cells by inhibiting the MET signaling pathway, providing a new treatment option for such patients. The development and application of tepotinib marks an important progress in the field of lung cancer treatment and brings more hope for survival to patients.

As for the cost of tepotinib, currently in the Chinese market, a box of tepotinib hydrochloride tablets (Tuodekang/TEPMETKO) with a specification of 225mg*60 tablets is priced at more than 30,000 yuan. This price is a considerable financial burden for many patients. In addition, as of now, tepotinib has not been included in my country’s medical insurance catalog, so patients need to purchase it at their own expense. However, with the advancement of medical technology and the improvement of drug accessibility, tepotinib may be included in medical insurance in the future, thus reducing the financial pressure on patients.

In overseas markets, generic versions of tepotinib provide patients with more choices. Lao ASEAN Pharmaceutical and Lao Lucius Pharmaceutical both produce generic versions of tepotinib, with the same specification of 225mg*60 tablets. The version of ASEAN Pharmaceuticals in Laos is priced at more than 9,000 yuan per box, while the version of Lucius Pharmaceuticals in Laos is more affordable, priced at more than 7,000 yuan per box. These generic versions are relatively less expensive, providing patients with more economical options.

However, when purchasing tepotinib or its generic version, patients must choose formal channels and pay attention to distinguishing the authenticity of the drug. Formal channels can not only ensure the quality and safety of drugs, but also provide professional medication guidance and after-sales services. Patients can consult professional medical institutions or pharmacists to learn about the source, authenticity, usage and dosage of the medicine to ensure the safety and effectiveness of the medicine.

To sum up, tepotinib, as a targeted treatment drug for non-small cell lung cancer, has a high price in the Chinese market and has not yet been included in medical insurance. However, generic versions in overseas markets offer patients more economical options. When purchasing, patients must choose formal channels and pay attention to distinguish the authenticity of the medicine to ensure the safety and effectiveness of the medicine. In the future, with the advancement of medical technology and the improvement of drug accessibility, tepotinib may be included in the scope of medical insurance, thus reducing the financial pressure on patients.